Tags

Type your tag names separated by a space and hit enter

Serum Uric Acid Level as a Biomarker in Idiopathic and Genetic (p.A53T Alpha-Synuclein Carriers) Parkinson's Disease: Data from the PPMI Study.
J Parkinsons Dis. 2020; 10(2):481-487.JP

Abstract

BACKGROUND

Blood uric acid level represents an emerging biomarker in Parkinson's disease (PD). Whether uric acid levels change in genetic forms of PD is just beginning to be explored.

OBJECTIVE

The aim of the present study was to assess differences in serum uric acid level among PD patients harboring the p.A53T mutation in the alpha-synuclein gene, idiopathic PD, and healthy controls.

METHODS

Longitudinal 5-year serum uric acid measurement data of 369 de novo idiopathic PD patients and 174 age- and gender-matched healthy controls have been downloaded from the Parkinson's Progression Markers Initiative (PPMI) database. Furthermore, we assessed baseline serum uric acid measurements of 24 p.A53T alpha-synuclein PD patients enrolled in PPMI and followed in our site as compared to 24 age-, gender- and disease duration-matched sporadic PD patients and 24 healthy controls.

RESULTS

Longitudinal serum uric acid measurements did not differ statistically between idiopathic PD patients and healthy controls (despite a trend for lower uric acid in the PD group) (p = 0.879). This was also true when male and female subgroups were assessed separately. The p.A53T SNCA mutation carrier PD group exhibited lower baseline serum uric acid level as compared to their matched healthy controls (p = 0.025).

CONCLUSION

In the present study we did not replicate the established lower serum uric acid measurements in PD patients as compared to controls using PPMI data, possibly due to the fact that PD patients in baseline visit were de novo and the average disease duration was shorter than that observed in most epidemiological PD studies. The faster progression rate and increased disease severity in p.A53T PD possibly correlate with the lower serum uric acid observed in this subgroup.

Authors+Show Affiliations

1st Neurology Clinic, Eginition Hospital, Athens University Medical School, Athens, Greece. 2nd Neurology Clinic, Attikon Hospital, Athens University Medical School, Athens, Greece.1st Neurology Clinic, Eginition Hospital, Athens University Medical School, Athens, Greece.Neurology Clinic, Henry Dunan Hospital, Athens, Greece.1st Neurology Clinic, Eginition Hospital, Athens University Medical School, Athens, Greece.1st Neurology Clinic, Eginition Hospital, Athens University Medical School, Athens, Greece. Nuclear Medicine Unit, Attikon Hospital, Athens, Greece.1st Neurology Clinic, Eginition Hospital, Athens University Medical School, Athens, Greece.1st Neurology Clinic, Eginition Hospital, Athens University Medical School, Athens, Greece. 2nd Neurology Clinic, Attikon Hospital, Athens University Medical School, Athens, Greece.2nd Neurology Clinic, Attikon Hospital, Athens University Medical School, Athens, Greece.2nd Neurology Clinic, Attikon Hospital, Athens University Medical School, Athens, Greece.1st Neurology Clinic, Eginition Hospital, Athens University Medical School, Athens, Greece.2nd Neurology Clinic, Attikon Hospital, Athens University Medical School, Athens, Greece.2nd Neurology Clinic, Attikon Hospital, Athens University Medical School, Athens, Greece.Nuclear Medicine Unit, Attikon Hospital, Athens, Greece.1st Neurology Clinic, Eginition Hospital, Athens University Medical School, Athens, Greece. Neurology Clinic, Philipps University, Marburg, Germany. Parkinson's disease and Movement Disorders Dept., HYGEIA Hospital, Athens, Greece.1st Neurology Clinic, Eginition Hospital, Athens University Medical School, Athens, Greece.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32176655

Citation

Koros, Christos, et al. "Serum Uric Acid Level as a Biomarker in Idiopathic and Genetic (p.A53T Alpha-Synuclein Carriers) Parkinson's Disease: Data From the PPMI Study." Journal of Parkinson's Disease, vol. 10, no. 2, 2020, pp. 481-487.
Koros C, Simitsi AM, Papadimitriou D, et al. Serum Uric Acid Level as a Biomarker in Idiopathic and Genetic (p.A53T Alpha-Synuclein Carriers) Parkinson's Disease: Data from the PPMI Study. J Parkinsons Dis. 2020;10(2):481-487.
Koros, C., Simitsi, A. M., Papadimitriou, D., Bougea, A., Prentakis, A., Papagiannakis, N., Pachi, I., Bozi, M., Antonelou, R., Angelopoulou, E., Beratis, I., Papageorgiou, S. G., Trapali, X. G., Stamelou, M., & Stefanis, L. (2020). Serum Uric Acid Level as a Biomarker in Idiopathic and Genetic (p.A53T Alpha-Synuclein Carriers) Parkinson's Disease: Data from the PPMI Study. Journal of Parkinson's Disease, 10(2), 481-487. https://doi.org/10.3233/JPD-191860
Koros C, et al. Serum Uric Acid Level as a Biomarker in Idiopathic and Genetic (p.A53T Alpha-Synuclein Carriers) Parkinson's Disease: Data From the PPMI Study. J Parkinsons Dis. 2020;10(2):481-487. PubMed PMID: 32176655.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum Uric Acid Level as a Biomarker in Idiopathic and Genetic (p.A53T Alpha-Synuclein Carriers) Parkinson's Disease: Data from the PPMI Study. AU - Koros,Christos, AU - Simitsi,Athina-Maria, AU - Papadimitriou,Dimitra, AU - Bougea,Anastasia, AU - Prentakis,Andreas, AU - Papagiannakis,Nikolaos, AU - Pachi,Ioanna, AU - Bozi,Maria, AU - Antonelou,Roubina, AU - Angelopoulou,Efthalia, AU - Beratis,Ion, AU - Papageorgiou,Sokratis G, AU - Trapali,Xenia Geronicola, AU - Stamelou,Maria, AU - Stefanis,Leonidas, PY - 2020/3/17/pubmed PY - 2021/7/27/medline PY - 2020/3/17/entrez KW - Parkinson’s disease KW - alpha-synuclein KW - genetic KW - uric acid SP - 481 EP - 487 JF - Journal of Parkinson's disease JO - J Parkinsons Dis VL - 10 IS - 2 N2 - BACKGROUND: Blood uric acid level represents an emerging biomarker in Parkinson's disease (PD). Whether uric acid levels change in genetic forms of PD is just beginning to be explored. OBJECTIVE: The aim of the present study was to assess differences in serum uric acid level among PD patients harboring the p.A53T mutation in the alpha-synuclein gene, idiopathic PD, and healthy controls. METHODS: Longitudinal 5-year serum uric acid measurement data of 369 de novo idiopathic PD patients and 174 age- and gender-matched healthy controls have been downloaded from the Parkinson's Progression Markers Initiative (PPMI) database. Furthermore, we assessed baseline serum uric acid measurements of 24 p.A53T alpha-synuclein PD patients enrolled in PPMI and followed in our site as compared to 24 age-, gender- and disease duration-matched sporadic PD patients and 24 healthy controls. RESULTS: Longitudinal serum uric acid measurements did not differ statistically between idiopathic PD patients and healthy controls (despite a trend for lower uric acid in the PD group) (p = 0.879). This was also true when male and female subgroups were assessed separately. The p.A53T SNCA mutation carrier PD group exhibited lower baseline serum uric acid level as compared to their matched healthy controls (p = 0.025). CONCLUSION: In the present study we did not replicate the established lower serum uric acid measurements in PD patients as compared to controls using PPMI data, possibly due to the fact that PD patients in baseline visit were de novo and the average disease duration was shorter than that observed in most epidemiological PD studies. The faster progression rate and increased disease severity in p.A53T PD possibly correlate with the lower serum uric acid observed in this subgroup. SN - 1877-718X UR - https://www.unboundmedicine.com/medline/citation/32176655/Serum_Uric_Acid_Level_as_a_Biomarker_in_Idiopathic_and_Genetic__p_A53T_Alpha_Synuclein_Carriers__Parkinson's_Disease:_Data_from_the_PPMI_Study_ L2 - https://content.iospress.com/openurl?genre=article&id=doi:10.3233/JPD-191860 DB - PRIME DP - Unbound Medicine ER -